CBER Director Focuses on Flexibility to Advance Regenerative Medicines – Regulatory Focus
Regulatory Focus |
CBER Director Focuses on Flexibility to Advance Regenerative Medicines
Regulatory Focus Peter Marks, director of the US Food and Drug Administration's (FDA) Center for Biologics Evaluation and Research (CBER) on Thursday said his office is equipped to support the development of cutting edge treatments, such as cell and gene therapies. |
